A Study of HRS-4729 Injection in Participants With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.

Also called NCT07843862

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07843862
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07843862. Randomized; quadruple masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
Intervention (Drug)
HRS-4729 Injection
Intervention (Drug)
Mazdutide
Intervention (Drug)
Placebo
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07843862
Content hash
8ebb34abe59364f0b721f261920d3e3cf7283263956926ea02330336c8c35d45